CD8A and neoplasm: Taken together, these results show that HF10 virotherapy combined with DTA-1 elicits a powerful therapeutic effect against tumors via the accumulation of CD8+ T cells, after tumor destruction by HF10 and the enhancement of tumor- and virus-specific CD8+ T cell responses directly or indirectly by depletion of immune-suppressive Treg cells at tumor sites by DTA-1.